Apures (A149300) Stock Overview
Engages in the development and commercialization of solutions for the bio and medical industries in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
A149300 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeApures Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩28.00 |
| 52 Week High | ₩292.00 |
| 52 Week Low | ₩17.00 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | -24.32% |
| 1 Year Change | -90.11% |
| 3 Year Change | -96.77% |
| 5 Year Change | -98.80% |
| Change since IPO | -98.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| A149300 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 0% | -4.1% | 1.6% |
| 1Y | -90.1% | 35.4% | 147.0% |
Return vs Industry: A149300 underperformed the KR Biotechs industry which returned 35.4% over the past year.
Return vs Market: A149300 underperformed the KR Market which returned 147% over the past year.
Price Volatility
| A149300 volatility | |
|---|---|
| A149300 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in KR Market | 16.2% |
| 10% least volatile stocks in KR Market | 4.7% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine A149300's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Choi Sundeok | www.apures.com |
Apures Co., Ltd. engages in the development and commercialization of solutions for the bio and medical industries in South Korea. It is involved in the development of MICROPIG, which are research and laboratory mini pig species to provide solutions through standardization of biomaterials for medical experiments and development of regenerative medicine treatments, including cell therapy and heterogeneous organs. The company provides Porcine Primary Cell for in vitro test.
Apures Co., Ltd. Fundamentals Summary
| A149300 fundamental statistics | |
|---|---|
| Market cap | ₩1.27b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
Is A149300 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A149300 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A149300 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/04 15:56 |
| End of Day Share Price | 2026/03/23 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Apures Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.